Blood Diagnostics for Evaluating
and Predicting Brain Damage
After A Concussion Or
Other Head Injury
In the last years traumatic brain injury awareness has come to the forefront more than ever before. Previously – concussion in sports and such were not identified as the danger it really is – but dedicated research, we now understand its ramifications more fully and the importance of rapid, objective diagnosis leading to effective treatment within an hour after the injury. The Blood Diagnostics for Evaluating and Predicting Brain Damage After A Concussion Or Other Head Injury makes this possibility a reality. It can change the way concussion and mild traumatic brain injury are diagnosed.
Alexandra Demetriou, University of Southern California, wrote an article for Medical Press titled Development of Precision Drug Delivery Tool to Treat Traumatic Brain Injury. It highlights the severity and frequency of traumatic brain injury (TBI). “The effects of TBIs on the American populace are nothing short of staggering. TBIs annually cause more deaths and lifelong disabilities than HIV/AIDS, breast cancer, multiple sclerosis and spinal cord injuries combined. Approximately one third of patients die due to secondary complications related to their TBIs, and in 2014, an average of 155 Americans died following a TBI each day. To compound this dramatic human toll, the economic burden of treating TBIs and their long-term side effects is estimated to be $60-76.5 billion each year. The causes of TBIs range from falls and forceful sports collisions to car accidents and severe blows to the head. Side effects vary widely, from cognitive challenges and dizziness to emotional changes and depression that can endure for days, weeks, or even years after the initial trauma. If effective treatments are not rapidly deployed, a TBI can trigger biochemical changes and inflammatory responses that progressively worsen a patient’s brain damage. To prevent serious side effects, doctors recommend that patients receive treatment within the “golden hour” after sustaining the injury”.
In 2018, the Food and Drug Administration approved a blood-based biomarker test for brain injury from Banyan Biomarkers Inc., the Banyan BTI (Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the evaluation of patients with suspected TBI. However, although publicized as a concussion test it is only available at hospital emergency departments not for diagnosis at a venue. One of the most unique qualities of the Blood Diagnostics for Evaluating and Predicting Brain Damage After A Concussion Or Other Head Injury is that it also provides for neurodegenerative disease prevention screening that the currently accepted injury markers do not.
PRODUCT FEATURES & BENEFITS
Special features
- It has a hybrid panel consisting of mitochondrial DNA and damage-associated molecular patterns (DAMPs)
- Identifies specific neuroinflammatory endophenotypes of traumatic brain injury (TBI), not just injury markers
- Allows for therapeutic target development (theranostics) that injury markers do not.
- Allows for neurodegenerative disease prevention screening that current injury markers do not.
- Can be easily used by non-medical professionals wherever the injury occurs – at venues like sports games, accidents, playgrounds and even battlefields.
- Interfaces with a smartphone, laptop, iPad, etc. which will add the information to the patients’ electronic medical record
PRODUCT DETAILS
The Blood Diagnostics for Evaluating and Predicting Brain Damage After A Concussion Or Other Head Injury scans the patient’s blood for specific biomarkers or indicators of concussion and sends the results to a smartphone which displays the results “like a traffic signal” – RED, YELLOW, GREEN. The data is then transmitted through encrypted software to the patients’ electronic medical record.
The Blood Diagnostics for Evaluating and Predicting Brain Damage After A Concussion Or Other Head Injury is covered by United States Utility Patent: 10,802,032
For additional information, licensing opportunities, and a full prospectus on the Blood Diagnostics for Evaluating and Predicting Brain Damage After A Concussion Or Other Head Injury contact:
BankOnIP
VP of Business Development
Email: info@BankOnIP.com
